Given the prevalence of liver disease – NAFLD, NASH, cirrhosis and even liver cancer – in the general population, I think the study findings below would be well-received. Especially, considering the implications of being able to treat most kinds of liver disease with something as simple as niacinamide (an NAD+ precursor), with likely synergistic effects when combined with an oxidizing agent (which increases oxidation of NADH back into NAD+) such as emodin, vitamin K, thymoquinone, methylene blue, tetracycline antibiotics, etc. I can’t get the full text of the study yet, as the study was just published, but once it becomes available I will modify the post to contain the oral supplementation protocol with NAD+ precursor(s) that the study mentions.
https://www.nature.com/articles/s41598-025-25496-1
“…We show that the size of the mitochondrial NAD+ pool in hepatocytes is regulated by SLC25A51 expression in vivo. We further find that selectively increasing mitochondrial NAD+ is sufficient to improve liver regeneration after partial hepatectomy, equivalent to the effect of systemic high-dose NAD+ precursor supplementation.”
